GlassScriptPhysician profile
Mahmoud K Effat
NPI 1730159450
$2,436.21
in general payments reported to CMS, 2019-2025
21 companies · $468 in 2025
The $468 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $116 · 2021: $32.42 · 2022: $64.55 · 2023: $565 · 2024: $289 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304 · Education: $17.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.27 |
| Education | $17.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $840.44 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $264.71 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $249.51 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $127.85 | 2023-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.50 | 2019-2023 | Spiriva Respimat |
| Genentech USA, INC. | $117.31 | 2019-2024 | Xolair |
| Kaleo, INC. | $114.34 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $114.04 | 2019 | |
| Mylan Specialty L.P. | $80.56 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $70.79 | 2019-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $66.30 | 2020-2025 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $53.04 | 2023-2025 | |
| Circassia INC. | $35.36 | 2019 | |
| Merck Sharp & Dohme LLC | $35.28 | 2019-2023 | |
| Pfizer INC. | $34.93 | 2021-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Ionis Pharmaceuticals, INC. | $19.34 | 2025 | Dawnzera |
| Biohaven Pharmaceuticals, INC. | $19.22 | 2021 | |
| Blueprint Medicines Corporation | $15.34 | 2025 | Ayvakit |
| Hikma Pharmaceuticals USA | $14.65 | 2023 | Ryaltris |
| Alk-Abello, INC | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Effat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.